Fortress Biotech, Inc. Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Amount
Fortress Biotech, Inc. (FBIO) reported Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Amount of $7.50 million for the 12-month period ending 2015-12-31, per its 10-K filed 2016-03-15.
Discontinued › Expense Statement
us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense · last filed 2016-03-15
- Fortress Biotech, Inc. effective income tax rate reconciliation, noncontrolling interest income (loss), amount for fiscal 2015 was $7.50M.
| Period end | Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Amount 12 month |
|---|---|
| 2015-12-31 | $7.50M 10-K · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |